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Single‑cell analysis of immune cell
transcriptome during HIV‑1 infection
and therapy
Justin Pollara1,2, Santosh Khanal3, R. Whitney Edwards1,2, Bhavna Hora2, Guido Ferrari1,2,
Barton F. Haynes1,2,4,5 and Todd Bradley2,3,4,6,7*

Abstract
Background: Cellular immune responses are phenotypically and functionally perturbed during HIV-1 infection, with
the majority of function restored upon antiretroviral therapy (ART). Despite ART, residual inflammation remains that
can lead to HIV-related co-morbidities and mortality, indicating that ART does not fully restore normal immune cell
function. Thus, understanding the dynamics of the immune cell landscape during HIV-1 infection and ART is critical to
defining cellular dysfunction that occurs during HIV-1 infection and imprints during therapy.
Results: Here, we have applied single-cell transcriptome sequencing of peripheral blood immune cells from chronic
untreated HIV-1 individuals, HIV-1-infected individuals receiving ART and HIV-1 negative individuals. We also applied
single-cell transcriptome sequencing to a primary cell model of early HIV-1 infection using CD4+ T cells from healthy
donors. We described changes in the transcriptome at high resolution that occurred during HIV-1 infection, and perturbations that remained during ART. We also determined transcriptional differences among T cells expressing HIV-1
transcripts that identified key regulators of HIV-1 infection that may serve as targets for future therapies to block HIV-1
infection.
Conclusions: This work identified key molecular pathways that are altered in immune cells during chronic HIV-1
infection that could remain despite therapy. We also identified key genes that are upregulated during early HIV-1
infection that provide insights on the mechanism of HIV-1 infection and could be targets for future therapy.
Keywords: HIV-1, Single-cell RNA-seq, HIV-1 infection, Immune cells
Background
HIV-1 infection leads to progressive loss of CD4+ T cells
that results in the development of acquired immunodeficiency syndrome (AIDS) [1, 2]. Initiation and adherent use of antiretroviral therapy (ART) can achieve viral
suppression that decreases HIV-1 mortality and reduces
the potential to transmit the virus to others [3–5]. In
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addition, the chronic inflammation caused by the virus
has been linked to non-AIDS related morbidity and
mortality making it clear that HIV-1 damages the host
immune system and ART may only partially restore the
damage and the level of activation of the immune system
[6–8]. These observations coupled with the number of
new HIV-1 infections that occur despite prevention and
therapeutic efforts highlight the need to better understand the impact HIV-1 has on host immune cell function
in order to understand infection and improve therapeutic
outcomes.
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Recently, high-throughput single-cell RNA sequencing (scRNA-seq) has emerged as a powerful tool to
understand the transcriptional differences in populations of cells at single-cell resolution and has provided
critical insights to understanding human disease pathogenesis. Single-cell approaches have been used to study
HIV-1 replication and infection, the heterogeneity of
the HIV-1 latent reservoir and the cellular response to
latency reversal agents [9–13]. Many of these studies
have focused on the effect of HIV-1 on CD4+ T cells and
have identified key pathways that are important for the
regulation of HIV-1 infection and latency. Study of nonCD4+ T cell populations has been limited, but investigators have demonstrated the complex interplay of innate
and adaptive immunity in the regulation of the HIV-1
broadly neutralizing antibody responses and viremia during infection [14–16].
Here, we sequenced the transcriptomes of 81,235
peripheral blood immune cells from six untreated
chronic HIV-1-infected individuals, three ART-treated
HIV-1-infected individuals and three HIV-1 seronegative individuals. We also identified cell types and states
that changed during infection and described changes in
immune cells that remain during ART. Finally, we used
the scRNA-seq approach in a primary cell model of acute
infection with HIV-1 to identify gene expression changes
that occur in cells that express HIV-1 compared to those
without HIV-1 transcript expression.

Results
scRNA‑seq identified distinct immune cell populations
during HIV‑1 infection

To determine the host immune cell transcriptional
changes during HIV-1 infection and ART, we performed
scRNA-seq of peripheral blood mononuclear cells

(PBMCs) from six untreated chronically HIV-1-infected
(untreated), three ART-treated HIV-1-infected (treated)
and three HIV-1 seronegative control (seronegative)
participants using the 10 × Genomics scRNA-seq platform (Table 1). The HIV-1-infected individuals on ART
had undetectable viral load, but were only on ART for
less than one year which could allow for residual viral
replication compared to individuals on ART for longer
periods. In order to normalize the data and to filter out
low-quality cells, we utilized the CellRanger aggregation
pipeline which normalized for effective sequencing depth
of each sample by subsampling the reads to the sample
with the lowest depth. Next, we excluded cells that had
greater than 20% of the genes that were mitochondrial
genes (Additional file 1: Fig. S1A). Finally, to correct for
any batch effects we used the Seurat analysis pipeline
Multi CCA method to regress out cell–cell variation in
gene expression in order to control for technical variation. This resulted in the elimination of 994 cells from the
final dataset. Among all individuals, we determined the
transcriptomes of 81,297 single cells detecting a median
of 951 genes per cell (Fig. 1A; Additional file 1: Table S1).
We first used an unsupervised analysis approach and
performed dimensionality reduction using Uniform
Manifold Approximation and Projection (UMAP) and
graph-based clustering to visualize and identify 23 transcriptionally distinct cell clusters in the total single cell
dataset (Fig. 1B). To define broad cell types contained in
each cluster we used the SingleR reference-based mapping to assign cell type identities to each cluster using
both the Immune cell expression and Monaco Immune
databases (Additional file 1: Table S2). In parallel, we
determined the pattern of expression of transcripts
that define immune cell identity to further classify the
cell clusters. We determined the expression of CD14

Table 1 Individual demographic and clinical information
Sample ID

Sample group

Gender

Race/ethnicity

Age

Viral load

CD4 count

ART

0036

HIV-1 seronegative

Male

Ngoni

45

NA

713

NA

1363

HIV-1 seronegative

Male

Chewa

34

NA

615

NA

1628

HIV-1 seronegative

Male

Lomwe

26

NA

908

NA

0501

HIV-1 untreated

Male

Black/African American

37

15,651

514

NA

0010

HIV-1 untreated

Male

Tumbuka

25

436,975

317

NA

0468

HIV-1 untreated

Male

Chewa

27

101,634

300

NA

0694

HIV-1 untreated

Female

Lomwe

26

> 750,000

301

NA

0782

HIV-1 untreated

Male

Xhosa

30

18,169

389

NA

0391

HIV-1 untreated

Female

Xhosa

26

> 750,000

236

NA

0592

HIV-1 ART treated

Male

Black/African American

24

< 400

566

Atripla (243 days)

0010

HIV-1 ART treated

Male

Tumbuka

25

< 400

243

Triomune (243 days)

0694

HIV-1 ART treated

Female

Lomwe

26

< 400

493

Triomune (191 days)
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expressed in monocytes; CD3D, CD4, CD8A expressed
in T cell populations; KLRC1 expressed in natural killer
(NK) cell populations; and CD79A expressed in B cell
populations (Additional file 1: Fig. S2A). We then identified the genes that were uniquely upregulated in each cell
cluster, and used the top three upregulated genes in each
cluster to generate a heatmap of gene expression across
the clusters (Fig. 1D; Additional file 2: Table S3).
Next, we used a supervised analysis approach to identify cell types but also more specific cell states using the
Azimuth reference-based mapping pipeline using refence
PBMC datasets. This identified naïve, memory, cytotoxic and regulatory populations of both CD4 and CD8
T cells, natural killer (NK) cell, B cells, monocyte, dendritic cells and small populations or platelet and erythroid cells (Fig. 1C). This analysis recapitulated many of
the expected immune cell lineages present in PBMCs.
We identified cells by the HIV group and found that
cells from HIV-1 infection (treated and untreated) had
overlapping populations with the HIV-1 seronegative
samples indicating overall similar transcriptomes of certain cellular populations, as well as clusters of cells that
displayed a unique transcriptome (Fig. 1D; Additional
file 1: Fig. S2). We then determined the fraction of cells
in each Azimuth-identified cell type that was had a frequency above 1% of the total cells (Fig. 1E). The most
abundant cell types in all groups were CD4 T central
memory, CD8 T effector memory and CD14 monocytes.
Individuals with HIV-1 infection (treated and untreated)
had increased frequency of CD8 T effector memory cells
(29.2%, ART HIV-1; 28.6%, Untreated HIV-1) compared
to seronegative individuals (14.2%; Fig. 1E). Conversely,
HIV-infected individuals had reduced frequencies of
CD4 T central memory cells (20.0%, ART HIV-1; 14.0%,
Untreated HIV-1) compared to seronegative individuals (27.2%; Fig. 1E). Individuals with treated or untreated
HIV-1 infection also had increased frequencies of CD14
(13.2% ART HIV-1; 19.3%, Untreated HIV-1) and CD16
(5.5%, ART HIV-1; 7.2%, Untreated HIV-1) monocyte
populations compared to the CD14 (11.5%) and CD16
(3.6%) monocyte populations in seronegative individuals (Fig. 1E). The reduction in CD4 T cell and increase
in CD8 T and monocyte populations were also evident
when the fraction of cells within each unsupervised
defined cluster (Additional file 1: Fig. S2C). Despite
ART treatment and no detectable HIV-1 viral load,
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transcriptionally unique populations of immune cells
were still present in the treated group especially among
monocytes and T cells (clusters 4, 6, 12, 16), indicating
that ART did not fully restore the immune cell transcriptional landscape after infection (Figs. 1E; Additional file 1: Fig. S2). Cluster 6 represented over 20% of
the cells in the treated group and contained a population
of regulatory T cells. Clusters 12 and 16 were also nearly
exclusively made up of cells in the treated group and represented populations of innate like cells (ILC) and CD16
monocytes, respectively (Additional file 1: Fig. S2C;
Additional file 2: Table S3). These data revealed that HIV
infection perturbed immune cell identity and that shortterm treatment to undetectable HIV-1 viral load did not
fully restore the cellular phenotypes.
Identification of differentially regulated genes in immune
cells from HIV‑1‑infected and seronegative individuals

We next determined the genes that were differentially
expressed in cells from the untreated HIV-1-infected
individuals compared with the seronegative individuals.
We found 96 genes that were upregulated and 45 genes
that were downregulated in the cells from untreated
HIV-1-infected individuals (Fig. 2A; Additional file 3:
Table S4). The top seven upregulated genes are all associated with interferon response (S100A8/9, MT2A,
IFITM3, IFI6, ISG15) [17], while the top downregulated
gene ZNF90 is a transcription factor with unknown roles
in immune cells followed by the genes CXCR4, IL7R and
BTG1, which are key regulators of lymphocyte proliferation and motility.
Next, we identified transcripts that were differentially
expressed in cells from HIV-1-treated individuals compared with the HIV-1 seronegative individuals to determine genes that are changed during HIV-1 infection
despite ART control of viral load. We found 83 genes
upregulated and 31 genes downregulated in cells from
the HIV-1-treated individuals compared to seronegative
individuals (Fig. 2B; Additional file 4: Table S5). CCL4
was the highest upregulated transcript in cells from
treated individuals. The CCL4 gene encodes the protein MIP-1b that can bind HIV-1 co-receptor CCR5 and
inhibit infection [18]. The next three upregulated genes
in treated individuals were DNAJB1, which is a part of
the HSP40 complex that has been shown to play a role
in anti-inflammatory processes in autoimmunity [19];

(See figure on next page.)
Fig. 1 scRNA-seq of peripheral immune cells identified distinct cellular populations. A Schematic of scRNA-seq experimental procedure using
peripheral blood mononuclear cells (PBMC) from 6 untreated chronic HIV-1-infected individuals, 3 ART-treated chronic HIV-1-infected individuals
and 3 HIV-1 seronegative individuals resulting in the analysis of 81,235 total PBMC cells. B UMAP analysis of all 81,235 cells and graph-based
clustering of cell populations resulted in the identification of 23 transcriptionally distinct clusters. Individual cells are colored by cluster identity. C
UMAP analysis with cell colored and labeled by cell identify determined by Azimuth reference. D UMAP analysis with individual cells colored by
sample group. E Bar graph showing the fraction of total single cells in each Azimuth defined cell type by group
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and RGS1 and SOD1, which are important for antiviral
immune responses [20]. The top downregulated transcripts in cells from treated individuals were the transcription factor ZNF90; NHSL2, which has unknown
function; and IL7R, which has been shown to play a role
in CD4 T cell loss during HIV-1 infection [21].
We performed Gene Set Enrichment Analysis (GSEA)
using the differentially expressed transcripts in untreated
HIV-1 or ART-treated HIV-1 compared to seronegative
individuals and plotted the hallmark pathways that were
significantly enriched (Fig. 2C, D). There were 10 hallmarks that had significant FDR-corrected q-values for
the untreated HIV-1 compared to seronegative controls
and 15 hallmarks that were significant in the ART-treated
individuals (Additional file 1: Table S6 and S7). Both
gene sets were enriched for pathways involved in inflammatory responses, complement immune responses and
interferon responses (Fig. 2C, D). There were also several enriched pathways involved in metabolism and cell
death. The Hallmark Inflammatory Response was significantly enriched in both HIV-1-infected groups (Fig. 2C,
D). These data demonstrated that genes associated with
the interferon response are upregulated in cells during
HIV-1-infection, and key immune genes important for
inflammatory processes and controlling virus replication,
such as CCL4, remain changed even during ART therapy.
T cells from ART‑treated individuals have increased
regulatory transcripts

We selected and performed graph-based clustering
of cells that identified as T cells and NK cells from the
larger dataset to determine higher resolution differences
in cellular clusters (Clusters 0, 1, 2, 3, 4, 6, 10, 12, 13, 14,
19, 21; Fig. 1). We identified 17 new distinct transcriptional clusters within this subset of cells (Fig. 3A). We
next determined the genes that were upregulated within
each cluster of cells, and generated a heatmap of the
top five genes that defined each cluster to further classify the identity of each cell cluster (Additional file 1: Fig.
S3A; Additional file 5: Table S8). We also determined the
expression of nine specific lineage-defining transcripts in
order to further classify the cell clusters (Additional file 1:
Fig. S3B). CD3D encodes for CD3 which identified T cell
populations and the T cells were further subdivided into
CD4+ and CD8+ T cells using CD4 and CD8A expression, respectively. This analysis identified a single major
cluster of CD4 T cells, but multiple CD8 T cell clusters
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that were transcriptionally distinct (Additional file 1: Fig.
S3B). We found that the T cells were segregated by naïve
T cell marker CCR7 as well as a marker of T cell activation MKI67. There were also smaller populations of T
cells with the regulatory marker FOXP3 and exhaustion
marker PD-1 (PDCD1; Additional file 1: Fig. S3B). We
also identified two major clusters of cells that lacked T
cell markers (cluster 11 and 13). Cluster 11 was further
classified as NK cells due to expression of granzyme B
and CD16 transcripts (GZMB and FCER1G) and cluster 13 had markers of monocyte populations (CD16,
FCER1G; lysozyme, LYZ; Additional file 1: Fig. S3). In
parallel, we utilized the reference-based cell identify
mapping approach Azimuth to identify cell populations.
This revealed similar cellular populations of CD4 and
CD8 naïve and memory populations, T regulatory cells,
and NK cells on the major group of single-cells on the
UMAP. There were also smaller segregated populations
of proliferating cell types, and platelets, B cells, monocytes and dendritic cells (Fig. 3B).
Cells from untreated HIV-1 and seronegative individuals had many overlapping clusters, while the cells from
the ART-treated individuals had more unique clusters of
T cells (Fig. 3C). Similar to what was observed when analyzing the entire PBMC dataset, there were smaller frequencies of CD4 TCM and increased frequencies of CD8
TEM cell populations in the cells from the untreated or
treated HIV-1 infected individuals compared to the cells
from the seronegative individuals (Fig. 3D). There was
a shift in the T cell populations for ART-treated HIV-1
individuals that were made up of clusters 4, 5 and 10
and represented mostly CD4 cytotoxic T lymphocytes
(CTL; Fig. 3A–D). These cells represented 6.14% of the
NK/T cells from ART-treated individuals compared to
2.46% and 1.67% of the untreated HIV-1 and seronegative
groups, respectively (Fig. 3D). Notably, these clusters had
upregulation of two genes that have been shown to play
a role in the development of regulatory T cells NFKBIA
and FTH1 [22] (Additional file 1: Fig. S3A).
Next we performed differential gene expression comparisons of the CD4+ and CD8+ T cell populations.
CD4+ and CD8+ T cells (CD4 and CD8A-expressing
cells, respectively) from untreated HIV-1 individuals had
upregulation of interferon response genes (IFI6, MT2A,
S100A8, S100A9) and downregulation of the transcription factor ZNF90 and IL7R that encodes CD127, important for T cell differentiation [23], when compared to

(See figure on next page.)
Fig. 2 Differentially expressed genes in untreated chronic and ART treated HIV-1-infected compared with HIV-1 seronegative cells. A–B Volcano
plot of genes that are significantly (P ≤ 0.05; Wilcoxon rank sum test, Bonferroni adjusted) different when comparing (A) Untreated HIV-1 vs.
Seronegative and B ART HIV-1 vs. Seronegative group cells. X-axis displays log2 fold-change of each significant gene. C–D Gene Set Enrichment
Analysis (GSEA) of the top enriched biological pathways in genes significantly altered in C untreated HIV-1 or D DART HIV-1. Pathways highlighted in
red are present in both groups. GSEA enrichment plot for the Hallmark_Inflammatory_Response feature is shown below each graph
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cells from seronegative donors (Additional file 6: Table S9
and Additional file 7: Table S10). When comparing differentially expressed genes in cells from ART individuals and seronegative, we found that CD4+ T cells had
upregulation of chemokines and IL1B, which contribute
to the proinflammatory state (Fig. 3E; Additional file 8:
Table S11). In CD8+ T cells from untreated HIV-1-infected compared to seronegative individuals, there is
upregulation of LGALS1 that encodes galectin-1 that has
been shown to induce apoptosis in effector T cells and
increase immunoregulatory roles of T cells [24] (Fig. 3F;
Additional file 9: Table S12). CD8+ T cells had upregulation of DUSP2 and RGS1 that are important for T cell
inflammation and cell migration [25] (Fig. 3F; Additional
file 9: Table S12). We observed a similar downregulation
of ZNF90 and IL7R when we compared ART to seronegative cells as when we compared untreated HIV cells were
compared to seronegative, indicating these transcripts
are changed in T cells during untreated or treated HIV-1
infection (Fig. 3E, F). These data demonstrated that
CD4+ and CD8+ T cells remain in a proinflammatory
state despite ART.
Increased expression of T cell activation
and long‑noncoding RNA transcripts regulate HIV‑1
infection

To identify genes that are critical for regulating CD4+
T cell resistance or sensitivity to initial HIV-1 infection,
we used scRNA-seq in a primary CD4+ T cell model of
HIV-1 infection. CD4+ T cells were enriched from the
PBMCs of two healthy HIV-1 uninfected donors and
stimulated for 72 h with recombinant human IL-2 and
antibodies directed against CD3 and CD28. After stimulation, the cells were infected with a full-length primary
HIV-1 infectious molecular clone (CH058; [26]) for
24 h. Cells were harvested and subjected to scRNA-seq
(Fig. 4A). We analyzed 7359 single T cells from the two
donors after filtering for poor quality cells (Additional
file 1: Fig. S1B). The cells from both donors clustered
similarly using UMAP (Fig. 4B). Annotation of referencebased cell identities using Azimuth revealed that most
cells were CD4 proliferating cells, with small populations
of cells with CD4 TCM identity (Fig. 4C). There were also
some cells that had gene expression profiles that matched
CD8 naïve, CD8 and NK proliferating cells (Fig. 4C).
Expression of HIV-1 gag transcripts was detected in 2005
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of the cells, indicating that after 24 h of virus exposure
approximately 27% of the cells had active viral transcription (Fig. 4D). In addition to HIV-1 gag transcript, we
identified 12 genes differentially expressed in cells with
HIV-1 transcripts compared with HIV-1 negative cells
(Fig. 4E, F). Two long-noncoding RNAs (NEAT1 and
MALAT1) were upregulated as were other markers of
T cell activation and interferon signaling (CD69, CCL3,
TNFRSF18, GZMB, GZMA, PRDM1, IFNG; Fig. 4E, F).
The three downregulated transcripts had variable function in cell metabolism, transcription and immune signaling (HSP90AA1, EIF5A, CYP1B1; Fig. 4F). Notably, the
top three genes that correlated (Pearson) with HIV-1 gag
expression levels were the two long-noncoding RNAs
NEAT1 and MALAT1, and PRDM1, which encodes the
transcriptional regulator BLIMP1 (Fig. 4G; Additional
file 10: Table S13). All three of these genes have been
implicated in controlling HIV-1 virus transcription and
latency [27–29]. Among the genes that anti-correlated
with gag expression were members of the SR protein
splicing factor family (SRSF2, SRSF3, SRSF7) that have
been shown to be important for HIV-1 RNA splicing
[30] (Fig. 4G; Additional file 10: Table S13). These data
show that the two long-noncoding RNAs NEAT1 and
MALAT1, SR protein splicing factors, and T cell activation status are critical for acute HIV-1 infection and viral
gene transcription. Future studies will be required to
determine if manipulation of these genes affects sensitivity to HIV-1 infection will be required.

Discussion
In this study, we have applied single-cell transcriptome
sequencing to map at high resolution the alterations and
cellular dynamics associated with HIV-1 infection and
therapy. Chronic infection with HIV-1 causes progressive
loss of immune cell function that leads to impaired immunity [31]. This immune dysfunction is partially restored
through antiretroviral therapy, but the molecular mechanisms of the development and restoration of immune
cell exhaustion are not fully understood, nor the immune
cell perturbations that remain despite therapy [32, 33].
Immune activation during HIV-1 infection is not limited to
the target CD4+ T cells but engages a range of molecular
and cellular processes in both the innate and adaptive arms
of the immune system [34]. Using single-cell transcriptomics, we were able to identify immune cell perturbations in

(See figure on next page.)
Fig. 3 Proinflammatory signatures in T cells despite therapy. A UMAP plot identifying T cell clusters that were isolated and reclustered for more
high-definition analysis revealing multiple cellular clusters. B UMAP analysis with cell colored and labeled by cell identify determined by Azimuth
reference. C UMAP plots of T cell clusters with cells labeled and colored by experimental group. D Bar graph showing the fraction of total single cells
in each Azimuth defined cell type by group. E–F Differentially expressed genes in Chronic or ART-treated HIV-1-infection compared to cells from
seronegative individuals in E CD4 T cells or F CD8 T cells. Each dot represents a gene and Bonferroni adjusted p value displayed on Y-axis and the
Log2 Fold change of expression displayed on the X-axis
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subsets of immune cells that were changed in individuals
with HIV-1 and some of which persisted in individuals on
therapy.
Confirming previously published studies, HIV-1 infection exhibited a proinflammatory immune state in all
immune cell types we analyzed, with evidence of upregulation of interferon response genes [13, 35, 36]. When comparing immune cells from ART-treated HIV-1-infected
individuals, we found higher frequencies of activated B
cells and proinflammatory CD4+ and CD8+ T cell populations than in seronegative controls. These data demonstrated that even when viral load is below the limit of
detection, changes in immune cells may persist. The shift of
immune cells to a more proinflammatory state could contribute to the comorbidities observed in HIV-1 individuals
despite ART [6, 37]. It will be important to study individuals at variable times after therapy initiation to determine if
and when immune cell states return to pre-infection levels.
Finally, we applied this technology to a primary CD4+
T cell model of early HIV-1 infection to identify genes
that directly contribute to sensitivity or resistance to
HIV-1 infection. We identified two long-noncoding RNAs,
NEAT1 and MALAT1 that correlated with HIV-1 transcript
levels. These two lncRNAs have previously been shown
to regulate T cell activation and control HIV-1 transcription, but their role in regulating the cell sensitivity to HIV-1
infection has not been determined [28, 29, 38]. Other studies using single-cell genomic approaches have determined
that HIV-1-infected cells undergo clonal expansion due to
antigenic or cytokine stimulation that help with seeding the
latent reservoir that are increased over time [39]. Understanding the clonal T cell dynamics during infection and
during therapy will be important for future studies. Moreover, studies have identified that the proviruses that make up
the latent reservoir are enriched in sequences that are present near ART initiation [40, 41]. This could suggest regulation of long-term persistence of HIV-infected cells. The
genes identified in our primary model of acute infection
could indicate that there are cellular pathways that restrict
HIV replication and establishment of persisting infected
cells for long-term. These genes, along with RNA splicing
factors identified in our analysis, may be targeted for future
therapies to block HIV-1 infection or control viral transcription in HIV-1 cure strategies.
There are limitations to our study, the major one is that
small exploratory study size. We know that demographic
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and other host factors such as age, sex, race/ethnicity,
other health conditions all can effect host immune cell
profiles. Moreover, the comparison of ART drug regimens and individuals with different duration of ART
would be informative that was not addressed here. Larger
studies that control for infection history ART class and
duration as well as account for the impact of demographics on immune cell profiles will be required to validate
any discoveries. Transcripts that have lower expression
in the single-cell datasets could also be critical for HIV
immune regulation but could have the impact reduced
due to low and variable detection. Improved scRNA-seq
sensitivity or targeted approaches on selected low-abundant transcripts could highlight the significance of these
genes. Another limitation is we studied the immune cells
in only the peripheral blood. Determining how HIV-1
infection and treatment influences cells in other tissues
such as the gut and lymphoid organs will be critical in
understanding how the virus impacts immune cells in
these critical tissue environments.

Conclusions
In summary, our study demonstrates the ability of
scRNA-seq to overcome the obstacles of the complexity and heterogeneity of the immune system. Using this
approach, we generated a high-resolution atlas of the
molecular changes that occur in blood immune cells
during HIV-1 infection and ART treatment, uncovering novel genes and inflammatory pathways that may be
important for restoring immune homeostasis in individuals with HIV-1 infection. Integration of the HIV-1 viral
genes to identify infected cells and determine transcriptome changes that occur during infection of the target
cells provides a framework to study HIV-1 and other viral
infections such as influenza, SARS-CoV-2 and measles
that are known to perturb the gene expression of host
cells. Taken together, using this approach in other infection and disease contexts will reveal unique and overlapping immune pathways that could be targeted with drugs
or treatment in the future.
Methods
Experimental model and subject details

Deidentified peripheral blood mononuclear cell (PBMC)
samples were used from existing cohorts of HIV-1-infected and seronegative individuals stored at the Duke

(See figure on next page.)
Fig. 4 CD4 T cell activation status and long-noncoding RNAs regulate early HIV-1 infection A overview of primary cell model of HIV-1 infection and
scRNA-seq. B UMAP plot of scRNA-seq of T cell data from two independent healthy individuals. Each point represents a single cell. C UMAP analysis
with cell colored and labeled by cell identify determined by Azimuth reference. D UMAP plot displaying HIV-1 gag gene expression in the individual
cells. E UMAP plots showing expression of transcripts that were significantly upregulated in T cells that had expression of HIV-1 gag compared to
cells that lacked expression. F Transcripts that were significantly changed in T cells that had expression of HIV-1 gag compared to cells that laced
detectable expression. G Top genes that correlated and anti-correlated (r, Pearson) with HIV-1 gag expression in all cells
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Fig. 4 (See legend on previous page.)
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Human Vaccine Institute that were approved by the
Duke Medicine Institutional Review Boards as well as the
ethics boards of the local sites. Individuals were mostly
male and of African descent (Table 1). These individuals
were a part of a large HIV-1 clinical study that received
longitudinal tissue sample collection. Whole venous
blood was drawn and then fractionated into PBMCs and
cryopreserved. This was an exploratory study, and the
selected participants were not statistically matched for
external factors such as age, sex, viral load or ethnicity.
Future studies should be performed to confirm these
cofounders. Cells from six untreated HIV-infected, three
ART-treated HIV-1-infected (HIV-1 viral load below the
limit of detection), and three HIV-1 seronegative (control) individuals were used to perform single-cell RNA
sequencing studies (10× Genomics; Table 1).
Primary cell model of HIV‑1 infection

PBMCs from two different HIV-1 seronegative individuals (not included in other analysis) were thawed
and T cells were activated by stimulation with CD3
(clone OKT3; eBioscience, 150 ng/mL) and CD28 (clone
CD28.2; BD Biosciences, 150 ng/mL) antibodies in RPMI
media supplemented with 20% FBS and recombinant
human IL-2 (NIH AIDS Reagent Program, Division of
AIDS, NIAID, National Institutes of Health, 30 U/mL).
Activation was allowed to proceed for 72 h at 37 °C 5%
CO2. CD4+ T cells were then enriched by removal of
CD8+ T cells using magnetic CD8 microbeads (Miltenyi Biotec, Germany). Cells were then infected with fulllength HIV-1 infectious molecular clone virus derived
from an infected individual CH058 [26] by spinoculation at 1200×g for 2 h at room temperature [42]. Infected
cells were incubated in RPMI media supplemented with
20% FBS and 30 U/mL IL-2 for 24 h. Cells were then harvested and washed with PBS for scRNA-seq.
scRNA‑seq library construction and sequencing

PBMCs were thawed, washed and placed in single-cell
suspensions with PBS + 0.04% BSA. Single-cells after
activation and 24 h infection from the primary cell model
of HIV-1 infection were also washed and also placed in
single-cell suspension with PBS + 0.04% BSA. Cellular suspensions were loaded on a GemCode Single-Cell
instrument (10× Genomics) to generate single-cell beads
in emulsion. Single-cell RNA-seq libraries were then
prepared using a GemCode Single Cell 3’ Gel bead and
library kit version 2 (10× Genomics). Single-cell barcoded cDNA libraries were quantified by quantitative
PCR (Kappa Biosystems) and sequenced on an Illumina
NextSeq 500 [9, 14, 43, 44]. Read lengths were 26 bp
for read 1, 8 bp i7 index, and 98 bp read 2. Cells were
sequenced to greater than 50,000 reads per cell.
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scRNA‑seq mapping and analysis

After sequencing, the Cell Ranger Single Cell Software
Suite (version 2.1.1) was used to generate sequencing
fastq files and to perform sample de-multiplexing, barcode processing, reference alignment and single-cell 3’
gene counting [45]. Reads were aligned to the human
genome (GRCH38) combined with the consensus
sequence of HIV-1 clade C gag derived from viruses in
the HIV Sequence Database (https://www.hiv.lanl.gov).
Clade C was selected due to it being the predominant circulating HIV-1 strain in southern Africa where most of
the individuals originate. Samples were aggregated using
the CellRanger Aggr function to create a single matrix of
cell barcodes and gene counts for the groups. During the
process each library is normalized for mapped sequencing depth. Reads are subsampled from higher-depth
libraries until they all have an equal number of reads per
cell that are confidently mapped to the transcriptome
in order to control for variation in the number of reads
per sample (sequencing depth). Finally, to correct for any
batch effects we used the Seurat analysis pipeline Multi
CCA method to regress out cell–cell variation in gene
expression in order to control for technical variation. The
union of variable genes across all individual samples are
utilized to renormalize the data.
Matrices of cell barcodes and gene counts generated by
Cell Ranger were loaded into Seurat R package (v3.2.3)
for graph-based cell clustering, dimensionality reduction
and data visualization [46–48]. We filtered low quality
cells that had lower than 200 expressed transcripts and
percentage of mitochondrial genes expressed greater
than 20% and for the primary cell model we reduced this
threshold to greater than 10% mitochondrial genes. We
included up to 45 PCA dimensions for the PBMCs and 48
PCA for the primary cell model for downstream graphbased clustering and UMAP visualization. All other
parameters we followed the default Seurat recommendations. SingleR (v. 1.0.5) was utilized to assist with immune
cell type identification [49]. Supervised identification of
cell identity and states were performed using Azimuth
[50]. Cells were annotated using the RunAzimuth, a Seurat object was provided as a query, function available on
azimuth package in R using default settings. The HumanPBMC dataset was used as the reference dataset for Azimuth [48]. The reported cell type annotations are based
on “celltype.I2” Azimuth output. Differentially expressed
genes between cell clusters or groups were determined
using Seurat by the Wilcoxon rank sum test. Genes that
correlated with HIV-1 transcript expression were calculated by Pearson correlation and corrected for multiple
comparisons using Bonferroni. Graphs and plots were
generated using the Seurat and ggplot2 (v3.3.3) R packages and Graphpad Prism version 8.
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GSEA v4.1.0 was used for gene set enrichment analysis. For the top 2000 variable genes, raw counts were
linearly transformed (using ScaleData function available on Seurat Package) and averaged to generate
expression dataset. Next, phenotype file was prepared
based on group information for the samples. Hallmark
gene sets (v7.2) and Human_HGNV_ID_MiSigDB
(v7.2) chip hosted on the GSEA-MSigDB file servers
were used as Gene sets and Chip annotation file respectively. Genes weren’t collapsed and “gene_set” parameter was used for permutation. While rest of the options
were run with default settings.
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